NOVAVAX ($NVAX) posted quarterly earnings results on Thursday, November 6th. The company reported earnings of -$0.62 per share, beating estimates of -$0.95 by $0.33. The company also reported revenue of $70,450,000, beating estimates of $52,928,238 by $17,521,762.
You can see Quiver Quantitative's $NVAX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVAVAX Hedge Fund Activity
We have seen 120 institutional investors add shares of NOVAVAX stock to their portfolio, and 117 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARK WEST ASSET MANAGEMENT LLC removed 2,528,857 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,931,799
- BANK OF AMERICA CORP /DE/ added 1,982,302 shares (+171.9%) to their portfolio in Q2 2025, for an estimated $12,488,502
- MILLENNIUM MANAGEMENT LLC added 1,160,814 shares (+134.8%) to their portfolio in Q2 2025, for an estimated $7,313,128
- ROYAL BANK OF CANADA added 1,062,449 shares (+7178.2%) to their portfolio in Q2 2025, for an estimated $6,693,428
- BNP PARIBAS FINANCIAL MARKETS removed 954,294 shares (-97.6%) from their portfolio in Q2 2025, for an estimated $6,012,052
- ALLIANZ ASSET MANAGEMENT GMBH added 872,987 shares (+162.6%) to their portfolio in Q3 2025, for an estimated $7,568,797
- UBS GROUP AG added 846,027 shares (+60.0%) to their portfolio in Q2 2025, for an estimated $5,329,970
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NOVAVAX Analyst Ratings
Wall Street analysts have issued reports on $NVAX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 10/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/28/2025
- B of A Securities issued a "Underperform" rating on 08/20/2025
- Citigroup issued a "Sell" rating on 06/17/2025
To track analyst ratings and price targets for NOVAVAX, check out Quiver Quantitative's $NVAX forecast page.
NOVAVAX Price Targets
Multiple analysts have issued price targets for $NVAX recently. We have seen 5 analysts offer price targets for $NVAX in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Brendan Smith from TD Cowen set a target price of $7.0 on 11/04/2025
- Pete Stavropoulos from Cantor Fitzgerald set a target price of $18.0 on 10/24/2025
- Sean Lee from HC Wainwright & Co. set a target price of $11.0 on 10/23/2025
- Alec Stranahan from B of A Securities set a target price of $7.0 on 08/20/2025
- Geoff Meacham from Citigroup set a target price of $6.0 on 06/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
